HK Stock Market Move | CLOVER BIO-B (02197) rose over 6% in the afternoon; positive data from Australian Phase II clinical trial of respiratory combination vaccine

CLOVER BIO-B (02197) rose over 6% in the afternoon. As of press time, it was up 5.24% at HK$2.01, with a turnover of HK$5.4861 million. On the news front, Clover Biopharmaceuticals recently announced positive preliminary data from a Phase II clinical trial conducted in elderly populations in Australia for its respiratory combination vaccine candidates SCB-1022 (RSV+hMPV) and SCB-1033 (RSV+hMPV+PIV3). In addition, the company has completed commercial-scale process scale-up of the antigen components related to SCB-1022/1033 in 2,000L bioreactors and completed multiple batches. The company's CEO, Liang Guo, said the "positive clinical trial results significantly reduce the risk of future late-stage development," while also validating the company's "differentiated Trimer-Tag platform" in developing multivalent protein respiratory vaccines.